Literature DB >> 21418669

Malaria: prevention in travellers.

Ashley M Croft1.   

Abstract

INTRODUCTION: Malaria transmission occurs most frequently in environments with humidity greater than 60% and ambient temperature of 25 °C to 30 °C. Risks increase with longer visits and depend on activity. Infection can follow a single mosquito bite. Incubation is usually 10 to 14 days but can be up to 18 months depending on the strain of parasite. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug preventive interventions in non-pregnant adult travellers? What are the effects of drug prophylaxis in non-pregnant adult travellers? What are the effects of antimalaria vaccines in adult and child travellers? What are the effects of antimalaria interventions in child travellers, pregnant travellers, and in airline pilots? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: aerosol insecticides, amodiaquine, air conditioning and electric fans, atovaquone-proguanil, biological control measures, chloroquine (alone or with proguanil), diethyltoluamide (DEET), dietary supplementation, doxycycline, electronic mosquito repellents, full-length and light-coloured clothing, insecticide-treated clothing/nets, mefloquine, mosquito coils and vapourising mats, primaquine, pyrimethamine-dapsone, pyrimethamine-sulfadoxine, smoke, topical (skin-applied) insect repellents, and vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21418669      PMCID: PMC3217660     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  103 in total

1.  Does mefloquine prophylaxis affect electroencephalographic patterns?

Authors:  Israel Potasman; Yoav Juven; Boaz Weller; Eli Schwartz
Journal:  Am J Med       Date:  2002-02-01       Impact factor: 4.965

Review 2.  Neurological effects associated with use of the insect repellent N,N-diethyl-m-toluamide (DEET).

Authors:  T G Osimitz; J V Murphy
Journal:  J Toxicol Clin Toxicol       Date:  1997

3.  Field evaluation of three plant-based insect repellents against malaria vectors in Vaca Diez Province, the Bolivian Amazon.

Authors:  Sarah J Moore; Annick Lenglet; Nigel Hill
Journal:  J Am Mosq Control Assoc       Date:  2002-06       Impact factor: 0.917

4.  The contribution of repellent soap to malaria control.

Authors:  A Kroeger; A Gerhardus; G Kruger; M Mancheno; K Pesse
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

5.  Guidelines for the prevention of malaria in travellers from the United Kingdom. PHLS Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine.

Authors:  D J Bradley; D C Warhurst
Journal:  Commun Dis Rep CDR Rev       Date:  1997-09-19

6.  Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy.

Authors:  R McGready; K A Hamilton; J A Simpson; T Cho; C Luxemburger; R Edwards; S Looareesuwan; N J White; F Nosten; S W Lindsay
Journal:  Am J Trop Med Hyg       Date:  2001-10       Impact factor: 2.345

7.  Combined pyrethroid and carbamate 'two-in-one' treated mosquito nets: field efficacy against pyrethroid-resistant Anopheles gambiae and Culex quinquefasciatus.

Authors:  P Guillet; R N'Guessan; F Darriet; M Traore-Lamizana; F Chandre; P Carnevale
Journal:  Med Vet Entomol       Date:  2001-03       Impact factor: 2.739

8.  Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

Authors:  D Overbosch; H Schilthuis; U Bienzle; R H Behrens; K C Kain; P D Clarke; S Toovey; J Knobloch; H D Nothdurft; D Shaw; N S Roskell; J D Chulay
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

9.  Malaria epidemiological situation in Italy and evaluation of malaria incidence in Italian travelers.

Authors:  R Romi ; G Sabatinelli ; G Majori
Journal:  J Travel Med       Date:  2001 Jan-Feb       Impact factor: 8.490

10.  Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.

Authors:  Judith Ling; J Kevin Baird; David J Fryauff; Priyanto Sismadi; Michael J Bangs; Mark Lacy; Mazie J Barcus; Robert Gramzinski; Jason D Maguire; Marti Kumusumangsih; Gerri B Miller; Trevor R Jones; Jeffrey D Chulay; Stephen L Hoffman
Journal:  Clin Infect Dis       Date:  2002-09-11       Impact factor: 9.079

View more
  4 in total

1.  Statement on Personal Protective Measures to Prevent Arthropod Bites: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  S Schofield; P Plourde
Journal:  Can Commun Dis Rep       Date:  2012-11-01

Review 2.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

3.  The effects of electricity network development besides routine malaria control measures in an underdeveloped region in the pre-elimination phase.

Authors:  Shahrokh Izadi
Journal:  Malar J       Date:  2016-04-18       Impact factor: 2.979

4.  Stand-by emergency treatment (SBET) of malaria in Spanish travellers: a cohort study.

Authors:  Pietro Ferrara; Cristina Masuet-Aumatell; Fernando Agüero; Josep Maria Ramon-Torrell
Journal:  Malar J       Date:  2018-04-02       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.